CLINICAL TRIALS PROFILE FOR RITUXAN HYCELA
✉ Email this page to a colleague
All Clinical Trials for RITUXAN HYCELA
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT02972840 ↗ | A Study of BR Alone Versus in Combination With Acalabrutinib in Subjects With Previously Untreated MCL | Recruiting | Acerta Pharma BV | Phase 3 | 2017-04-05 | This study is evaluating the efficacy of acalabrutinib in combination with bendamustine and rituximab (BR) compared with placebo plus BR in subjects with previously untreated mantle cell lymphoma. |
| NCT03467867 ↗ | A Study of Venetoclax and Rituximab/Hyaluronidase Human in Relapsed/Refractory CLL | Recruiting | Hackensack Meridian Health | Phase 2 | 2018-04-26 | This is an open-label, multicenter, Phase II study to investigate the efficacy and safety of venetoclax in combination with Rituximab/hyaluronidase human in participants with relapsed or refractory chronic lymphocytic leukemia (CLL). |
| NCT03467867 ↗ | A Study of Venetoclax and Rituximab/Hyaluronidase Human in Relapsed/Refractory CLL | Recruiting | Georgetown University | Phase 2 | 2018-04-26 | This is an open-label, multicenter, Phase II study to investigate the efficacy and safety of venetoclax in combination with Rituximab/hyaluronidase human in participants with relapsed or refractory chronic lymphocytic leukemia (CLL). |
| NCT03623373 ↗ | Acalabrutinib With Bendamustine / Rituximab Followed by Cytarabine / Rituximab for Untreated Mantle Cell Lymphoma | Active, not recruiting | Acerta Pharma BV | Phase 2 | 2018-11-29 | This study is designed to evaluate the efficacy and safety of acalabrutinib plus bendamustine and rituximab followed by acalabrutinib plus cytarabine and rituximab in subjects with treatment naïve mantle cell lymphoma (MCL), as a preparation for a larger cooperative group trial with the goal of achieving a standard induction regimen for MCL in transplant eligible patients. The investigators hypothesize that the addition of acalabrutinib to BR/CR regimen will prove safe and increase the complete response (CR) rate as well as minimal residual disease (MRD) negativity pre-transplant, thus improving clinical outcomes. |
| NCT03623373 ↗ | Acalabrutinib With Bendamustine / Rituximab Followed by Cytarabine / Rituximab for Untreated Mantle Cell Lymphoma | Active, not recruiting | Washington University School of Medicine | Phase 2 | 2018-11-29 | This study is designed to evaluate the efficacy and safety of acalabrutinib plus bendamustine and rituximab followed by acalabrutinib plus cytarabine and rituximab in subjects with treatment naïve mantle cell lymphoma (MCL), as a preparation for a larger cooperative group trial with the goal of achieving a standard induction regimen for MCL in transplant eligible patients. The investigators hypothesize that the addition of acalabrutinib to BR/CR regimen will prove safe and increase the complete response (CR) rate as well as minimal residual disease (MRD) negativity pre-transplant, thus improving clinical outcomes. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for RITUXAN HYCELA
Condition Name
Clinical Trial Locations for RITUXAN HYCELA
Trials by Country
Clinical Trial Progress for RITUXAN HYCELA
Clinical Trial Phase
Clinical Trial Sponsors for RITUXAN HYCELA
Sponsor Name
